Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

compulsory licensing

- PMLiVE

India’s export curbs raise fears of global drug shortages

Decision comes amid increased concerns over coronavirus outbreak

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Inizio

- PMLiVE

Patently unclear?

The challenge of protecting  biotech innovations

- PMLiVE

Innovation and the pharma patent court

As the UK prepares to exit the European Union a unified patent system is still essential

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

- PMLiVE

GSK tops Access to Medicines Index for fifth time running

Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag

- PMLiVE

Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

Eli Lilly HQ

Lilly’s president and chief executive John Lechleiter to retire

David Ricks selected to succeed Lechleiter from 1 January 2017

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links